An analysis of more than 300 patients with hematologic cancer found that cognitive impairment had a negative effect on outcomes, whereas age and IADLs did not.
This study also showed a gradual increase in cognitive impairment at 12 months that persisted at 24 and 36 months for patients receiving endocrine therapy alone.
Proton pump inhibitors are used to control negative GI effects in patients receiving chemotherapy for breast cancer. But their availability as over-the-counter medications may be leading to overuse, making another common adverse effects worse.
In an evaluation of the use of geriatric assessments by specially trained oncology nurses in the care of older patients with cancer, particularly when patients are susceptible to potential loss of autonomy, researchers found physicians often seek nurse assessments.
Thinking and Living With Cancer (TLC) sought to determine the effects of breast cancer treatment and age on cognitive function in older breast cancer survivors over time.
Study data suggest that cognitive impairments may be associate with worse survival among patients with hematologic cancer.
Data on psychosocial and psychiatric variables of patients with HNC prior to treatment was analyzed to determine the extent of cognitive impairment and quality of life for patients with head and neck cancer, and its impact on patient outcomes.
A double-blind study compared the effectiveness of lorazepam plus haloperidol with haloperidol alone in reducing agitation in patients with advanced cancer.
The researchers found that the majority of patients had no frank detectable cognitive impairment after undergoing skull base irradiation.
Moderate-to-vigorous physical activity was found to improve working memory and executive function in survivors of breast cancer.
